Mineralys Therapeutics In...

13.55
-0.45 (-3.21%)
At close: Apr 03, 2025, 3:59 PM
13.53
-0.18%
After-hours: Apr 03, 2025, 05:20 PM EDT

Mineralys Therapeutics Statistics

Share Statistics

Mineralys Therapeutics has 62.78M shares outstanding. The number of shares has increased by 26.46% in one year.

Shares Outstanding 62.78M
Shares Change (YoY) 26.46%
Shares Change (QoQ) 26.15%
Owned by Institutions (%) 93.04%
Shares Floating 36.97M
Failed to Deliver (FTD) Shares 58.95K
FTD / Avg. Volume 6.18%

Short Selling Information

The latest short interest is 1.87M, so 3.76% of the outstanding shares have been sold short.

Short Interest 1.87M
Short % of Shares Out 3.76%
Short % of Float 7.94%
Short Ratio (days to cover) 7.47

Valuation Ratios

The PE ratio is -3.36 and the forward PE ratio is -2.56. Mineralys Therapeutics's PEG ratio is -0.04.

PE Ratio -3.36
Forward PE -2.56
PS Ratio 0
Forward PS 1.4
PB Ratio 3.12
P/FCF Ratio -3.59
PEG Ratio -0.04
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 14.02, with a Debt / Equity ratio of 0.

Current Ratio 14.02
Quick Ratio 14.02
Debt / Equity 0
Debt / EBITDA 0
Debt / FCF 0
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-3.49M
Employee Count 51
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by 8.14% in the last 52 weeks. The beta is 1.51, so Mineralys Therapeutics's price volatility has been higher than the market average.

Beta 1.51
52-Week Price Change 8.14%
50-Day Moving Average 11.78
200-Day Moving Average 12.24
Relative Strength Index (RSI) 50.95
Average Volume (20 Days) 954K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -192.4M
Net Income -177.81M
EBITDA -192.4M
EBIT n/a
Earnings Per Share (EPS) -3.66
Full Income Statement

Balance Sheet

The company has 114.09M in cash and 0 in debt, giving a net cash position of 114.09M.

Cash & Cash Equivalents 114.09M
Total Debt 0
Net Cash 114.09M
Retained Earnings -302.52M
Total Assets 205.9M
Working Capital 190.71M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -166.31M and capital expenditures -96K, giving a free cash flow of -166.41M.

Operating Cash Flow -166.31M
Capital Expenditures -96K
Free Cash Flow -166.41M
FCF Per Share -3.43
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

MLYS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for MLYS is $33, which is 136.6% higher than the current price. The consensus rating is "Buy".

Price Target $33
Price Target Difference 136.6%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score 31.57
Piotroski F-Score 1